Edition:
United Kingdom

MyoKardia Inc (MYOK.OQ)

MYOK.OQ on NASDAQ Stock Exchange Global Select Market

59.75USD
17 Sep 2018
Change (% chg)

-- (--)
Prev Close
$59.75
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
110,240
52-wk High
$66.40
52-wk Low
$32.85

Chart for

About

MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializi... (more)

Overall

Beta: --
Market Cap(Mil.): $1,434.94
Shares Outstanding(Mil.): 34.96
Dividend: --
Yield (%): --

Financials

  MYOK.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -0.67 -- --
ROI: -18.14 1.78 14.61
ROE: -19.24 3.29 16.33

BRIEF-MyoKardia Announces Pricing Of Public Offering Of Common Stock

* MYOKARDIA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

23 May 2018

BRIEF-MyoKardia Says Offering 3.75 Mln Common Shares

* MYOKARDIA ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

21 May 2018

BRIEF-MyoKardia Doses First Patient In Pioneer Open-Label Extension Study Of Mavacamten

* MYOKARDIA DOSES FIRST PATIENT IN PIONEER OPEN-LABEL EXTENSION STUDY OF MAVACAMTEN FOR SYMPTOMATIC, OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

10 May 2018

BRIEF-MyoKardia Q1 Loss Per Share $0.50

* Q1 EARNINGS PER SHARE VIEW $-0.29 -- THOMSON REUTERS I/B/E/S

08 May 2018

BRIEF-MyoKardia Begins Dosing In Phase 2 MAVERICK-HCM Clinical Trial Of Mavacamten

* HCM TRIAL ARE ANTICIPATED IN SECOND HALF OF 2019 Source text for Eikon: Further company coverage:

02 Apr 2018

Earnings vs. Estimates